TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

TD Cowen has recently initiated TG Therapeutics Inc common stock (TGTX) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on August 2, 2023, Goldman had raised the ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

TG Therapeutics (TGTX) came out with quarterly earnings of ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...